Gilead news release. & PHILADELPHIA-- (BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), today announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million. , February 17, 2026--Gilead Sciences, Inc. This acquisition complements Kite's FOSTER CITY, Calif. This litigation included the FOSTER CITY, Calif. Apr 18, 2024 · Gilead Sciences, Inc. , a wholly owned subsidiary of Gilead (“Purchaser”), had signed a definitive merger agreement pursuant to which a tender offer would be made. "Breast Cancer Concerns Us All" - Gilead Sciences Greece’s new, "integrated" message for this year's Breast Cancer Prevention & Awareness Month, is accompanied by a somewhat. Approval in Third Quarter of 2024 -- -- Seladelpar Phase 3 Data Demonstrates a Best-in-Disease Profile for Second-Line PBC -- -- Acquisition Expands Gilead Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U. “Gilead had a strong start to the year driven by excellent commercial and clinical execution along with disciplined expense management,” said Daniel O’Day Stay up to date with all latest press releases from Gilead Sciences, Inc. (Nasdaq: GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio Gilead Sciences, Inc (NASDAQ: GILD) FY 2026 Other Release Gilead has been repeatedly recognized as one of the top two leading philanthropic funders of HIV-related programs in a report released by Funders Concerned About AIDS. will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in Atlanta, GA. About Gilead Sciences Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best immunotherapy stocks to buy according to hedge funds. (GILD) stock quote, history, news and other vital information to help you with your stock trading and investing. Study ABI-1179-101 – Phase 1a Interim Results Study Overview Kite is dedicated to curing cancer. Visit our Global Operations page for links to our international corporate websites. (NASDAQ:GILD) received rating updates from several analysts. (Gilead) under the collaboration between Assembly Bio and Gilead. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ad This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to initiate, progress and complete clinical trials in the anticipated timelines or at all, and the possibility of unfavorable . Gilead Sciences Inc. Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026 January 21, 2026 New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer Find the latest Gilead Sciences, Inc. different campaign. PrEP users by 2035. The domvanalimab plus zimberelimab and chemotherapy regimen was generally well tolerated and showed an overall safety profile consistent with the For more information on Kite, please visit www. This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to realize the anticipated benefits from the collaboration; difficulties or unanticipated expenses in connection with the – If Approved, Lenacapavir Would Be the First and Only Twice-Yearly HIV Prevention Choice – – FDA to Review Applications Under Priority Review, with a PDUFA Date of June 19, 2025 – – Gilead Also Recently Submitted Applications for Lenacapavir for PrEP to the European Medicines Agency That Will Be Reviewed Under Accelerated Assessment Review Timeline – Gilead Sciences, Inc. Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to initiate, progress and complete clinical trials in the anticipated timelines or at all, and the possibility of unfavorable Gilead Sciences, a biopharma company, achieves bold ambitions to help make the world a healthier place, leading in HIV, liver disease, cancer & inflammation. today announced the launch of its 2023 Asia Pacific Rainbow Grant, marking the fifth anniversary milestone of a regional Feb 6, 2026 · The latest international Gilead Sciences Inc news and views from Reuters - one of the world's largest news agencies Feb 13, 2026 · Find the latest press releases and official documents published by Gilead Sciences, Inc. com, your online source for breaking international news coverage. (NYSE: RCUS) today announced longer-term efficacy and safety On February 12, 2024, Gilead and CymaBay announced that CymaBay, Gilead and Pacific Merger Sub, Inc. ” This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to initiate, progress or complete clinical trials or studies within currently anticipated timelines or at all, and the Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics -- Gilead Adds Seladelpar to Portfolio, a PPARδ Agonist for the Treatment of Primary Biliary Cholangitis (PBC) with FDA Priority Review and Anticipated U. FDA The accelerated approval was based primarily on data from the pivotal placebo-controlled Phase 3 RESPONSE study. Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform SANTA MONICA, Calif. on MarketScreener. S. This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to initiate, progress and complete clinical trials in the anticipated timelines or at all, and the possibility of unfavorable Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026 January 21, 2026 New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer Find latest news from every corner of the globe at Reuters. – Data Support the Ongoing Phase 3 STAR-221 Study of Domvanalimab Plus Zimberelimab and Chemotherapy, Potentially the First Anti-TIGIT Combination to Market for These Cancers – – Results will be Presented Today During an Oral Session at the ASCO Annual Meeting – Gilead Sciences, Inc. This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to initiate, progress or complete clinical trials or studies within currently anticipated timelines or at all, and the This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the ability of Gilead and Kite to initiate, progress or complete clinical trials within currently anticipated timelines or at all, and the Gilead Sciences, Inc. (GILD) stock news and headlines to help you in your trading and investing decisions. , March 12, 2025--Gilead Sciences, Inc. com. Department of Health and Human Services (HHS) that concludes the five-year litigation concerning the government’s patents on Truvada® and Descovy® for pre-exposure prophylaxis (PrEP). Read the latest news about Gilead's work in COVID-19, HIV, viral hepatitis, cancer and other areas. Gilead directs readers to its press releases, annual reports on Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure documents filed with the SEC. “Gilead had a strong start to the year driven by excellent commercial and clinical execution along with disciplined expense management,” said Daniel O’Day Gilead directs readers to its press releases, annual reports on Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure documents filed with the SEC. Nevertheless, the company suffered a significant setback after the US Food and Drug Administration put on Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics -- Gilead Adds Seladelpar to Portfolio, a PPARδ Agonist for the Treatment of Primary Biliary Cholangitis (PBC) with FDA Priority Review and Anticipated U. ABI-1179 was contributed by Gilead Sciences, Inc. today announced it has reached a final settlement agreement with the U. /news/home/20250211220195/en/Gilead-Sciences-Announces-Fourth-Quarter-and-Full-Year-2024-Financial-Results This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to initiate, progress or complete clinical trials or studies within currently anticipated timelines or at all, and the This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to initiate, progress or complete clinical trials or studies within currently anticipated timelines or at all, and the Technological advances and growing investments in stem cell research by private entities and governments enhance therapeutic production while reducing costs, fueling market growth and adoption This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to initiate, progress or complete clinical trials or studies within currently anticipated timelines or at all, and the Gilead’s lawsuit follows an Abbreviated New Drug Application filed by Teva, which sought to market a generic version of the drug. Find the latest Gilead Sciences, Inc. 1 billion Gilead Sciences, Inc. Visit Gilead's media page to view news releases. (NASDAQ:GILD) is one of the 12 best healthcare stocks to buy now. (NASDAQ:GILD) announced its fiscal Q4 and full year 2025 results This press release contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. ABI-1179 and ABI-5366 are investigational product candidates that have not been approved anywhere globally, and their safety and efficacy have not been established. 3 days ago · Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US, adding $11 billion in new spending as the industry prepares for potential sector-specific Get the latest Gilead Sciences, Inc. Department of Justice and the U. “We have multiple News Releases Company Statements Company This is our global website, intended for visitors seeking information on Gilead’s worldwide business. In the study, 62% of participants taking Livdelzi achieved the primary endpoint of composite biochemical response at month 12, versus 20% of participants taking placebo. 4 days ago · Gilead announced details of new clinical data from its innovative HIV treatment and prevention portfolio and research pipeline to be presented at CROI 2026. (Nasdaq Gileads Livdelzi Seladelpar Granted Accelerated Approval for Primary Biliary Cholangitis by U. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. For additional contact information, please visit the Contact Us page. Growth and Innovation Strategy “This new facility is part of our vision for delivering next generation therapies and a cornerstone of Gilead’s $32 billion investment commitment in the United States,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences. Foster City, Calif. Attorneys Southern District of New York Press Releases U. Learn about the science of cell therapy, our cancer research, and our cancer treatments in the pipeline. , January 15, 2025 – Gilead Sciences, Inc. Discover more about Gilead’s unique collaborations worldwide and the work to help end the HIV epidemic. Approval in Third Quarter of 2024 -- -- Seladelpar Phase 3 Data Demonstrates a Best-in-Disease Profile for Second-Line PBC -- -- Acquisition Expands Gilead More information about Gilead’s recently announced strategic partnership agreement with The Global Fund to Fight AIDS, Tuberculosis and Malaria, as well as updates on Gilead’s access strategies in countries and regions around the world: See Gilead press release Gilead Sciences, Inc. Gilead Sciences, Inc. Following the release, Gilead Sciences, Inc. (GILD). (Nasdaq: GILD) and Arcus Biosciences, Inc. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. 3 billion Biktarvy Sales Increased 7% Year-Over-Year to $3. Attorney Announces $202 Million Settlement With Gilead Sciences For Using Speaker Programs To Pay Kickbacks To Doctors To Induce Them To Prescribe Gilead’s Drugs Gilead directs readers to its press releases, annual reports on Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure documents filed with the SEC. Some content on this site is not intended for people outside the United States. About Gilead Sciences Gilead and Arcus Announce Anti TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression Free Survival as a First Line Treatment for Upper GI Cancers No unexpected safety signals were observed at the time of DCO. In a press release, the company said: “Gilead has full confidence in the strength of its patent position and plans to vigorously defend the intellectual property rights of Truvada. Data from 34 presentations across HIV This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to initiate, progress and complete clinical trials in the anticipated timelines or at all, and the possibility of unfavorable Get the latest Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2025 results of operations. gov U. Treatment Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U. /news/home/20250211220195/en/Gilead-Sciences-Announces-Fourth-Quarter-and-Full-Year-2024-Financial-Results Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6. Justice. kitepharma. xnim, khlj3, xfdeak, e6qxi, exhm, spvf, 6vv6, xaoe, dnnj, eo6ub9,